On Oct. 20-22, the 5th International Molecular Imaging Symposium (IMIS 2023)- the Xiamen University, also known as the Innovative Radiopharmaceutical Development and Clinical Transformation Seminar were held grandly. As an influential and leading event in the field of molecular imaging, this forum brings together more than 500 industry elites, including academicians, experts, physicians, and entrepreneurs, to deliver keynote speeches, participate in professional conferences, and discuss the development direction of molecular imaging.

Dongcheng International Pharmaceutical Innovation Application Base project is important for the Group to promote the future development of the nuclear medicine. Since the start of the project, it has made rapid progress and has received widespread attention and expectations from all sectors. Recently, “Yantai News” focused on the construction of the Blue Medicine Valley Life Island project and provided a detailed introduction to the LNC innovative drugs.

Recently, at the European Association of Nuclear Medicine 36th Annual Congress (EANM2023, Sept. 9-13th, 2023), Vienna, Austria, LNC once again introduced its innovative research achievements in the field of radionuclide diagnosis and treatment, which obtained great attention and recognition from international peers. 

On Jul. 19, LNC successfully held its first shareholders' meeting in 2023 at the headquarters of DC PHARMA. 

On Jun. 21, the 16th meeting of the 5th Board of Directors of DC PHARMA approved the “Proposal on Introducing Investors through Capital Increase and Share Expansion of Wholly-Owned Subsidiaries”. It was agreed that Yantai Lannacheng Biotechnology Co., Ltd., a holding subsidiary of DC PHARMA, will introduce 9 investors, including DC PHARMA, Jinglin Jingying, Xindognneng Fund, Dongneng Jiayuan, Yeda Investment, Boxin Investment, Blue Medicine Valley, Yuanhe Chunxi, and Mouxin Investment, through capital increase and share expansion. A total of RMB 200 million was invested to subscribe for the new registered capital of RMB 9.773908 million at the consideration of RMB 20.4626 per share. 

On May 16, 2023, the launching ceremony of the installation and decoration engineering of the LNC Muping project was grandly held at the Blue Medicine Valley Life Island Industrial Park, Muping District. 

Recently, LNC PHARMA received the IND approval from the US FDA regarding the 177Lu-LNC1003 injection for the Phase I clinical trial, which will benefit patients with advanced prostate cancer in the near future.

On Jan. 6, 2023, LNC PHARMA received the IND approval from the US FDA regarding the 177Lu-LNC1004 injection for the Phase I clinical trial.